User:Elizabeth Yowell/SandboxGiavanna
From Proteopedia
< User:Elizabeth Yowell(Difference between revisions)
| (3 intermediate revisions not shown.) | |||
| Line 1: | Line 1: | ||
| - | =SARS CoV-2 Protein Inhibitors (AHB2 and LCB1/LCB3)= | + | <scene name='10/1076049/Antibody/1'>Text To Be Displayed</scene>=SARS CoV-2 Protein Inhibitors (AHB2 and LCB1/LCB3)= |
<StructureSection load='7UHB' size='350' frame= 'true' side= 'right' caption='AHB2 Inhibitor 7UHB' scene ='10/1075216/Practice/1'> | <StructureSection load='7UHB' size='350' frame= 'true' side= 'right' caption='AHB2 Inhibitor 7UHB' scene ='10/1075216/Practice/1'> | ||
| Line 8: | Line 8: | ||
The enzyme angiotensin converting enzyme 2 (ACE2) is attached to our cell membranes bound to a receptor binding domain (RBD) <ref name="Borkotoky">DOI:10.1007/s11033-022-08193-4</ref>. The spike protein of SARS-CoV-2 enters our bodies and binds to the RBD, allowing the spike protein access to ACE2 and our host cells <ref name=”Jackson”>DOI:10.1038/s41580-021-00418-x</ref>. Once the spike protein has access to our host cells, it is able to further infect our cells and spread the virus throughout our bodies, causing us to get sick. In order to create an effective vaccine, the pathway between the spike protein and the RBD needs to be [https://www.sciencedirect.com/science/article/pii/S0166354223000190 interrupted]. | The enzyme angiotensin converting enzyme 2 (ACE2) is attached to our cell membranes bound to a receptor binding domain (RBD) <ref name="Borkotoky">DOI:10.1007/s11033-022-08193-4</ref>. The spike protein of SARS-CoV-2 enters our bodies and binds to the RBD, allowing the spike protein access to ACE2 and our host cells <ref name=”Jackson”>DOI:10.1038/s41580-021-00418-x</ref>. Once the spike protein has access to our host cells, it is able to further infect our cells and spread the virus throughout our bodies, causing us to get sick. In order to create an effective vaccine, the pathway between the spike protein and the RBD needs to be [https://www.sciencedirect.com/science/article/pii/S0166354223000190 interrupted]. | ||
| + | <scene name='10/1076049/Antibody/2'>Antibody Vaccine</scene> | ||
| + | |||
| + | <scene name='10/1076049/Antibody/4'>Antibody Binding Site</scene> | ||
<scene name='10/1075216/Practice/2'>Overview Image</scene> | <scene name='10/1075216/Practice/2'>Overview Image</scene> | ||
| + | |||
| + | <scene name='10/1076049/Antibody_overview/1'>Antibody Overview</scene> | ||
Where do we begin... <ref name="Hunt">DOI: 10.1126/scitranslmed.abn1252</ref>. | Where do we begin... <ref name="Hunt">DOI: 10.1126/scitranslmed.abn1252</ref>. | ||
| Line 17: | Line 22: | ||
[[Image:Spike with Covid.png|400 px|lef|thumb|Figure Legend: The coolest image of this protein EVAH and it was handmade!!!<ref name="Hunt">DOI: 10.1126/scitranslmed.abn1252</ref>.]] | [[Image:Spike with Covid.png|400 px|lef|thumb|Figure Legend: The coolest image of this protein EVAH and it was handmade!!!<ref name="Hunt">DOI: 10.1126/scitranslmed.abn1252</ref>.]] | ||
| + | |||
| + | [[Image:LCB_Method.png|400 px|left|thumb|Figure Legend:Figure 3:The use of the De Novo protein design to create the LCB inhibitors.]] | ||
==Function== | ==Function== | ||
| Line 36: | Line 43: | ||
*Shea Bailey | *Shea Bailey | ||
*Matthew Pereira | *Matthew Pereira | ||
| + | |||
| + | |||
| + | <scene name='10/1076049/Ace2andrbd/1'>ACE2</scene> | ||
Current revision
=SARS CoV-2 Protein Inhibitors (AHB2 and LCB1/LCB3)=
| |||||||||||
References
PDB Files
[1]https://www.rcsb.org/structure/7UHB
Student Contributors
- Giavanna Yowell
- Shea Bailey
- Matthew Pereira
